How many half-lives are required to reach steady-state concentration (Css)?

Under continuous constant infusion or regular repeated dosing, approximately 4 to 5 elimination half-lives are required to reach > 95% of steady-state plasma concentration.

What happens to clearance if plasma protein binding is displaced?

Displacing a highly protein-bound drug increases its free (unbound) fraction (fu). For low hepatic extraction drugs, total clearance increases while unbound concentration remains largely steady.

PK/PD Modeling Principles & Equations | CologyLabs Educational Resource | CologyLabs

Pharmacokinetics and Pharmacodynamics (PK/PD) Modeling: Bridging In Vitro Assays and In Vivo Efficacy

Master the mathematical modeling of ADME parameters, compartment kinetics, non-linear Michaelis-Menten elimination, and dynamic effect-site concentrations for pharmacy students.

Dr. Rajesh K. Nair, M.Pharm, Ph.D.

Professor of Biopharmaceutics and Pharmacokinetics

Published: October 25, 2026Updated: Nov 3, 202610 min read

1. The Core Paradigm of PK/PD

Pharmacology is broadly divided into two complementary disciplines:

Pharmacokinetics (PK): What the biological body does to the drug (Absorption, Distribution, Metabolism, Excretion).

Pharmacodynamics (PD): What the drug does to the body (Receptor binding, Signal transduction, Physiological effect).

Integrating both domains into a cohesive PK/PD model enables pharmaceutical scientists to predict clinical dose regimens, calculate therapeutic windows, and minimize toxic peak concentrations.

\text{Dose} \xrightarrow{\text{Pharmacokinetics}} \text{Plasma Concentration } C(t) \xrightarrow{\text{Pharmacodynamics}} \text{Biological Response } E(t)

2. Fundamental Pharmacokinetic Parameters and Equations

Understanding these foundational mathematical relationships is essential for every pharmacy undergraduate and post-graduate:

Apparent Volume of Distribution ($V_d$)

The hypothetical volume into which the total amount of administered drug (A) would need to be uniformly distributed to achieve the measured plasma concentration (C_p):

V_d = \frac{\text{Dose}}{C_0} = \frac{A}{C_p}

A high V_d (> 0.6 \text{ L/kg}) signifies extensive tissue and lipophilic binding (e.g., Chloroquine, Digoxin), whereas a low V_d (~ 0.1 \text{ L/kg}) indicates confinement to the vascular compartment (e.g., Warfarin, Heparin).

Total Body Clearance ($CL$)

The volume of plasma completely cleared of drug per unit time by renal, hepatic, and biliary elimination routes:

CL = \frac{\text{Rate of Elimination}}{C_p} = k_e \cdot V_d = \frac{F \cdot \text{Dose}}{\text{AUC}_{0-\infty}}

Where:

k_e is the first-order elimination rate constant (\text{time}^{-1})

\text{AUC} is the Area Under the Plasma Concentration-Time Curve

F is systemic bioavailability (0 \le F \le 1)

Elimination Half-Life ($t_{1/2}$)

The duration required for the plasma drug concentration to decrease by 50% under first-order kinetics:

t_{1/2} = \frac{\ln(2)}{k_e} = \frac{0.693 \cdot V_d}{CL}

3. Pharmacodynamic Emax Model and Hill Coefficient

The concentration-effect relationship is modeled using the sigmoidal E_{\max} equation:

E = \frac{E_{\max} \cdot C^n}{\text{EC}_{50}^n + C^n}

Where:

E is the observed biological effect

E_{\max} is the maximum achievable pharmacological effect (efficacy)

\text{EC}_{50} is the concentration eliciting 50% of E_{\max} (potency)

n is the Hill coefficient (slope factor representing cooperativity)

4. Linear vs. Non-Linear (Michaelis-Menten) Kinetics

While most therapeutic drugs exhibit linear first-order elimination at therapeutic concentrations, certain drugs (e.g., Phenytoin, Ethanol, high-dose Aspirin) transition into capacity-limited non-linear clearance as metabolic enzymes become saturated:

-\frac{dC}{dt} = \frac{V_{\max} \cdot C}{K_m + C}

When C \ll K_m, the process mirrors first-order kinetics; when C \gg K_m, the elimination rate becomes constant (V_{\max}), representing zero-order kinetics where small dose increments produce catastrophic surges in plasma concentration.